References
- Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148:95–102.
- Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10.
- Preventing and Managing the Global Epidemic of Obesity. Report of the world health organization consultation of obesity. Geneva: WHO, 1997.
- Guinot C, Latreille J, Perrussel M, Doss N, Dubertret L; French Psoriasis Group. Psoriasis: characterization of six different clinical phenotypes. Exp Dermatol. 2009;18:712–719.
- http://www.ofdt.fr/BDD/publications/docs/eftxfbr6.pdf.
- Bogdanovica I, Godfrey F, McNeill A, Britton J. Smoking prevalence in the European Union: a comparison of national and transnational prevalence survey methods and results. Tob Control. 2011;20:e4.
- Wolkenstein P, Revuz J, Roujeau JC, Bonnelye G, Grob JJ, Bastuji-Garin S; French Society of Dermatology. Psoriasis in France and associated risk factors: results of a case-control study based on a large community survey. Dermatology. 2009;218:103–109.
- Stringhini S, Spencer B, Marques-Vidal P, Waeber G, Vollenweider P, et al. Age and gender differences in the social patterning of cardiovascular risk factors in Switzerland: The CoLaus Study. PLoS One. 2012;7:e49443.
- Ahlehoff O, Skov L, Gislason G, Lindhardsen J, Kristensen SL, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med. 2012; in press.
- Di Lernia V, Tasin L, Pellicano R, Zumiani G, Albertini G. Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis. J Dermatolog Treat. 2012;23:404–409.
- De Marco G, Cattaneo A, Battafarano N, Lubrano E, Carrera CG, Marchesoni A. Not simply a matter of psoriatic arthritis: epidemiology of rheumatic diseases in psoriatic patients. Arch Dermatol Res. 2012;304:719–726.
- Golpour M, Hosseini SH, Khademloo M, Ghasemi M, Ebadi A, et al. Depression and Anxiety Disorders among Patients with Psoriasis: A Hospital-Based Case-Control Study. Dermatol Res Pract. 2012;2012:381905.
- Hoffmann JH, Hartmann M, Enk AH, Hadaschik EN. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. Br J Dermatol. 2011;165:1355–1358.
- Escande H, Livideanu CB, Steiner A, Lahfa M, Marguery MC, Mazereeuw JH, et al. Incidence and risk factors for treatment failure with infliximab in psoriasis. J Eur Acad Dermatol Venereol. 2013; doi: 10.1111/jdv.12077.
- Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45:1558–1565.
- Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. 2011;13:R94.
- Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C. Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care Res (Hoboken). 2010;62:1128–1143.
- Söderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol. 2012;41:1–9.
- Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum. 2011;63:359–364.
- Mattey DL, Dawes PT, Hassell AB, Brownfield A, Packham JC. Effect of psychological distress on continuation of anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. J Rheumatol. 2010;37:2021–2024.
- Tak PP. A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology (Oxford). 2012;51:600–609.
- Downs AM. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab. Br J Dermatol. 2010;163:433–434.
- Vitiello M, Grant A, Kerdel FA. Ustekinumab: when everything else fails? Int J Dermatol. 2011;50:478–482.
- Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol. 2009;124:1022–1010; e1-395.